Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
Avex Life Sciences Corp
AstraZeneca Plc
Cerevel Therapeutics LLC
Karu Therapeutics Inc
Lan Sheng Biomedicine Suzhou Co Ltd
NeuroHealing Pharmaceuticals Inc
NeuroSolis Inc
Presbyopia Therapies LLC
Sosei Heptares
Suven Life Sciences Ltd
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize CHRM4 for Drug-Induced Dyskinesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0016878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis and Cognitive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropicamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6000918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6001852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
Featured News & Press Releases
Sep 10, 2020: Avex Life Sciences announces completion of AVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome clinical trial
Aug 19, 2020: Avex Life Sciences announces commitment for Fincial Investment by Shake It Up Foundation for Parkinson’s Research for clinical trial of AVEX?2-73 (Blarcamesine) in patients with Parkinson’s disease
Aug 05, 2020: Avex Life Sciences receives TGA special access scheme approval for AVEX2-73 (blarcamesine) for Alzheimer’s disease patients
Aug 03, 2020: Karu Therapeutics announces topline data from phase 1b trial evaluating KarXT on experimentally induced pain in healthy volunteers
Jul 02, 2020: Avex starts dosing patients in Rett syndrome trial
Jul 01, 2020: Avex Life Sciences announces first patient dosed in EXCELLENCE Phase 2/3 clinical trial of AVEX?2-73 (Blarcamesine) in patients with Rett Syndrome
Jun 23, 2020: Karu Therapeutics announces positive outcome of end-of-phase 2 meeting with the FDA for KarXT for the treatment of acute psychosis in patients with schizophrenia
Jun 16, 2020: Avex Life Sciences announces exceeding of enrollment target for the AVEX 2-73 (blarcamesine) U.S. phase 2 Rett Syndrome clinical trial
Jun 04, 2020: Avex Life Sciences receives regulatory approval from Health Cada and UK MHRA expanding phase 2b/3 AVEX2-73 (blarcamesine) into multitiol clinical trial for Alzheimer’s disease
May 27, 2020: Karu Therapeutics to present additiol data from the phase 2 clinical trial of KarXT for the treatment of psychosis in patients with schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
Apr 23, 2020: Avex Life Sciences announces publication of clinical data for AVEX2-73 (blarcamesine) in Alzheimer’s Disease
Feb 24, 2020: Avex Life Sciences announces publication of foundatiol data for AVEX2-73 (blarcamesine) in multiple sclerosis (MS)
Feb 03, 2020: Avex Life Sciences announces Fast Track Desigtion granted by U.S. FDA for AVEX2-73 (blarcamesine) clinical development program for the treatment of Rett Syndrome
Jan 27, 2020: Avex Life Sciences announces achievement of enrollment target for the AVEX2-73 (blarcamesine) phase 2 Parkinson’s Disease Dementia (PDD) clinical trial
Jan 08, 2020: Avex Life Sciences issued new U.S. patent for AVEX2-73 treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Anavex Life Sciences Corp, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Cerevel Therapeutics LLC, H2 2020
Pipeline by Karuna Therapeutics Inc, H2 2020
Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, H2 2020
Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2020
Pipeline by NeuroSolis Inc, H2 2020
Pipeline by Presbyopia Therapies LLC, H2 2020
Pipeline by Sosei Heptares, H2 2020
Pipeline by Suven Life Sciences Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020